跳至主要内容
临床试验/NCT01350791
NCT01350791已完成不适用

Evaluation of Effectiveness and Safety of PROMUS Element™ in Routine Clinical Practice; A Multicenter, PROSPECTIVE OBSERVATIONAL STUDY

Seung-Jung Park1 个研究点 分布在 1 个国家目标入组 3,001 人开始时间: 2010年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
3,001
试验地点
1
主要终点
Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)

研究概览

简要总结

This study is a non-randomized, prospective, open-label registry to compare the efficacy and safety of Promus Element stents versus first-generation drug-eluting stent (DES) in patients with coronary artery disease.

详细描述

The Element Stent platform features a proprietary Platinum Chromium Alloy, designed specifically for coronary stents. This alloy, coupled with a new stent architecture, is designed to enable thinner struts, increased flexibility and a lower profile while improving radial strength, recoil and visibility. In addition, the PROMUS Element Stent System incorporates the new Apex™ Dilatation Catheter technology, designed to enhance deliverability to complex lesions.

Currently, there have been limited data regarding comparison of PROMUS Element stent with first-generation DES in routine clinical practice. Therefore, we perform large-scale real-world registry of PROMUS Element stents.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients receiving Promus Element stents
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

排除标准

  • Patients with a mixture of other DESs
  • Terminal illness with life expectancy <1 year
  • Patients with cardiogenic shock

结局指标

主要结局

Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)

时间窗: 12 months post stenting procedure

次要结局

  • Myocardial infarction(yearly up to 5 years)
  • Death (all-cause and cardiac)(30 days)
  • Target Vessel Revascularization(yearly up to 5 years)
  • Composite of cardiac death or MI(yearly up to 5 years)
  • Stent thrombosis(yearly up to 5 years)
  • Composite of death or MI(yearly up to 5 years)
  • Death (all cause and cardiac)(yearly up to 5 years)
  • Target lesion revascularization(yearly up to 5 years)
  • Procedural success(defined as achievement of a final diameter stenosis of <30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization)(3 days in average)

研究者

发起方
Seung-Jung Park
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Seung-Jung Park

MD,PhD

CardioVascular Research Foundation, Korea

研究点 (1)

Loading locations...

相似试验